Original article
At the beginning of this year, the kick-off workshop of TMF e. took place in Berlin. V. took place at the start of the implementation phase of the BMBF-funded model register of health services research. With a funding volume of 13.5 million euros, six BMBF-funded model healthcare research registers are implementing their innovative projects: Fever App, HerediCaRe, ParaReg, RECUR, SOLKID-GNR living donation register and the TOFU register in the last round against 13 applications in a selection process. According to TMF, the aim of the funded projects is to build new, patient-related registers on important questions in health care research. To do this, they must meet high quality standards and have a model character.
02.04.2020
After the innovation fund projects Cardiolotse (MVF 04/19), Stroke OWL (MVF 05/19), Mambo (MVF 06/19) and RubiN (MVF 01/20), the ZSE-DUO project, the dual, is presented in this issue Pilot structure to clarify unclear diagnoses in centers for rare diseases. ZSE-DUO expands the previously presented health or patient pilot approaches to include a very early aspect of care management. The ZSE-DUO project also comes with another novelty: It is probably the first attempt in the world to diagnose patients suffering from a rare disease right from the start by a competent team of doctors and psychiatrists, then treat them initially and provide support - if necessary also with telemedical support – into standard care.
02.04.2020
With the rapid report on the use of registers in the course of benefit assessment presented by IQWiG on January 10, 2020, an important milestone has been reached. That in itself is remarkable. Anyone who knows the previous attitude, especially that of the current head of the institute, Jürgenwickeler, knows why.
02.04.2020
“Detailed analyzes of methodological literature as well as intensive discussions with registry operators and external medical biometricians have led us to the opinion that with high-quality patient registries it is possible to set up studies on these registries and to use the collected care-related data for the extended benefit assessment of medicines.” That such words ever passed the lips of Prof. Dr. Jürgen Wascher, the director of the IQWiG institute, no one would have even suspected. diaperer, who has always been an apologist for pure science, explained in the cover interview with “Monitor Healthcare Research” (01/18) at the beginning of 2018 that good registries can be used to answer questions about patient adherence, doctors’ prescribing behavior, check-ups and much more can answer more, but they are not suitable for questions of benefit. Now, with the rapid report presented at the beginning of the year “Concepts for the generation of care-related data and their evaluation for the purpose of assessing the benefits of medicines in accordance with Section 35a SGB V” 1, he changed his previously negative attitude quite drastically and even assumes that “the first “Data from high-quality registries can be incorporated into benefit assessments of medicines.” Even if he restricts registration studies that could be carried out both with and without randomization as a sinequa non condition: “The decisive factor in both cases is the high quality of the data.”
02.04.2020
Cytostatics have been the drug of choice in oncological therapy for many years. For a good 20 years, they have been supplemented by biologics and other specific active ingredients, which can be seen as important treatment alternatives for some of the over 200 different types of cancer that have now been identified. The new, so-called targeted therapies are causing sales for pharmaceutical companies in oncology, but also the costs for the community of insured persons in the statutory health insurance, to rise significantly. To what extent does this overview of the market for oncologic drugs and in particular targeted therapies show.
02.04.2020
“We want to make our contribution to making medicine a little better.” That’s what Prof. Dr. med. Jörg F. Debatin MBA, Chairman of the health innovation hub (hih), in the cover interview with “Monitor Healthcare Research”. Among other things, Debatin and his team, which he has gathered around him in a very multi-professional manner, want to help ensure that the “digitalization that is quite theoretically anchored in the law actually reaches the patient”. That makes hih, as Debatin explains in the interview, “very free in our ideas and not obligated to anyone else.” And since the end of hih's business activities is already certain at the end of 2021, there is no need to worry about follow-up orders, extensions or the like.
02.04.2020
“It was and is time to supplement the Charité’s scientific profile with the area of health services research.” With this commitment, Prof. Dr. phil. Adelheid Kuhlmey, Director of the Institute for Medical Sociology and Rehabilitation Science at the Charité, the 1st Charité Healthcare Research Congress, an initiative of the newly founded platform - Charité Healthcare Research, of which she is the spokesperson. This dedication and commitment to health services research is something very special for this university hospital, which is one of the most research-intensive medical institutions in Germany, with its 279 professors and 7,500 students, over 17,000 employees and over 3,000 beds. And it is by no means an ill-advised act, as the idea of establishing an in-house platform for health services research and perpetuating this with its own congress has been carefully considered over the last year and a half.
17.01.2020
Das Institut für Medizinische Soziologie und Rehabilitationswissenschaft (IMSR) der Charité – Universitätsmedizin Berlin wurde bereits im März 2002 neu gegründet. Und damit in genau dem Jahr, in dem an der Universität zu Köln der 1. Deutsche Kongress für Versorgungsforschung (DKVF) ausgerichtet wurde. Doch das war noch lange nicht der Beginn des IMSR, denn es steht in einer langen Tradition medizinsoziologischen und sozialmedizinischen Denkens innerhalb der Berliner Universitätsmedizin und gehörte bereits 1970 zur Struktur des damals entstandenen Zentralinstituts für Soziale Medizin an der Freien Universität Berlin. Geleitet wird das Institut von Prof. Dr. phil. Adelheid Kuhlmey, die im „Nebenjob“ seit 2014 die Prodekanin für Studium und Lehre an der Charité ist.
17.01.2020
On the occasion of the merger of the three associations German Healthcare Export Group (GHE), German Healthcare Partnership (GHP) and German-Sino Healthcare Group (GSHCG) on January 1, 2020 to form the GHA - German Health Alliance, the members of the new initiative of the Federal Association of Germans Industry e. V. (BDI) met together for the first time. At this meeting at the end of last year in Berlin, the GHA's German Global Health Award 2019 was presented to Professor Dr. Detlev Ganten awarded.
17.01.2020
Nach den Innovationsfonds-Projekten Cardiolotse (MVF 04/19), Stroke OWL (MVF 05/19) und Mambo (MVF 06/19) wird in dieser Ausgabe das Projekt RubiN vorgestellt, das – nach Aussage des Akronyms – erforschen will, wie die Versorgung von geriatrischen Menschen „Regional ununterbrochen betreut im Netz“ funktionieren kann. Das mit rund acht Millionen Euro aus dem Innovationsfonds geförderte Modellvorhaben hat ganz aktuell einen wichtigen Meilenstein erreicht: Ende letzten Jahres wurden in fünf Modellregionen insgesamt 3.200 geriatrische Patienten in das Projekt aufgenommen, was bedeutet, dass nun ausgebildete Care- und Casemanager pro Region 640 Senioren im Alltag begleiten, die bei Ärztenetzen angesiedelt sind und zentral koordiniert werden.